Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
← catalyst calendarSponsored by Belite Bio, Inc (industry) · BLTE — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
104actual
Sites
19
Countries
Australia, Belgium, China +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-28 | actual | When the study began enrolling |
| Primary completion | 2025-08-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-11 | actual | The whole study's end, after follow-up |
| First posted | 2022-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Stargardt Disease 1
Interventions
- Drug: Tinlarebant
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTo measure change in atrophic lesion size (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baseline
measured Baseline thru month 24
Permalink · BLTE's whole pipeline · Catalyst calendar · Every registered study · What changed